Summary: The paper contains the most important updates of GINA recommendations that have been signaled in the latest version of the Pocket guide form 2019. There are significant changes in the approach to the treatment of intermittent and mild asthma (withdrawal of recommendations for SABA in monotherapy) as well as severe asthma (strengthening the position of biologic therapies and warning against adverse events due to oral corticosteroids). The authors discuss the causes and effects of the changes.